Evolvable signaling networks of receptor tyrosine kinases: Relevance of robustness to malignancy and to cancer therapy

Molecular Systems Biology

Volumn 3, Issue , 2007, Pages

  Amit, Ido ^a,c   Wides, Ron ^b   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Cancer therapy; Evolvability; Feedback control; Growth factor; Oncogene; Receptor tyrosine kinase; Robustness

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER ANTIBODY; CANERTINIB; CDP 791; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MATUZUMAB; MDX 210; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PANITUMUMAB; PERTUZUMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; XL 880;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER GROWTH; CANCER THERAPY; DISEASE COURSE; DRUG APPROVAL; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENE DUPLICATION; GENE FUSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION; UBIQUITINATION; ANIMAL; CHEMISTRY; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR EVOLUTION; NEOPLASM;

ANIMALS; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; FEEDBACK, BIOCHEMICAL; HUMANS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 36849068465     PISSN: 17444292     EISSN: 17444292     Source Type: Journal    
DOI: 10.1038/msb4100195     Document Type: Review

References (95)

1. Alon U (2003) Biological networks: the tinkerer as an engineer. Science 301: 1866-1867
2. Alon U (2006) An Introduction to Systems Biology: Design Principles of Biological Circuits. Taylor and Francis: CRC Press
3. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y (2007) A module of negative feedback regulators defines growth factor signaling. Nat Genet 39: 503-512
4. Aroian RV, Koga M, Mendel JE, Ohshima Y, Sternberg PW (1990) The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature 348: 693-699
5. Barabasi A-L, Oltavi ZN (2004) Network biology: understanding the cell's functional organization. Nat Rev Genet 5: 101-113
6. Barbasi A-L, Alberts R (1999) Emergence of scaling in random networks. Science 286: 509-512
7. Baselga J (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178
8. Ben-Kasus T, Schechter B, Sela M, Yarden Y (2007) Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol 1: 42-54
9. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature 411: 355-365
10. Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, Fischer S, Romeo G, Rossi B (1997) The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15: 2257-2265
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578
12. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
13. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR (2006) Emerging roles of pseudokinases. Trends Cell Biol 16: 443-452
14. Bradham CA, Foltz KR, Beane WS, Arnone MI, Rizzo F, Coffman JA, Mushegian A, Goel M, Morales J, Geneviere AM, Lapraz F, Robertson AJ, Kelkar H, Loza-Coll M, Townley IK, Raisch M, Roux MM, Lepage T, Gache C, McClay DR et al (2006) The sea urchin kinome: a first look. Dev Biol 300: 180-193
15. Burgess MR, Sawyers CL (2006) Treating imatinib-resistnat leukemia: the next generation targeted therapies. ScientificWorldJournal 6: 918-930
16. Carballo E, Lai WS, Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281: 1001-1005
17. Carlson JM, Doyle J (2000) Highly optimized tolerance: robustness and design in complex systems. Phys Rev Lett 84: 2529-2532
18. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
19. Casci T, Freeman M (1999) Control of EGF receptor signalling: lessons from fruitflies. Cancer Metastasis Rev 18: 181-201
20. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446
21. Courtneidge SA, Smith AE (1984) The complex of polyoma virus middle-T antigen and pp60c-src. EMBO J 3: 585-591
22. Csete M, Doyle J (2004) Bow-ties, metabolism and disease. Trends Biotechnol 22: 446-450
23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
24. Dikic I, Giordano S (2003) Negative receptor signalling. Curr Opin Cell Biol 15: 128-135
25. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521-527
26. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172
27. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, Sommergruber W, Kraut N, Ullrich A, Fassler R, Klein R (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12: 568-573
28. Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69 (Suppl 3): 11-16
29. Freeman M (2000) Feedback control of intercellular signalling in development. Nature 408: 313-319
30. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773
31. Goldberg JM, Manning G, Liu A, Fey P, Pilcher KE, Xu Y, Smith JL (2006) The dictyostelium kinome - analysis of the protein kinases from a simple model organism. PLoS Genet 2: e38
32. Gore MF, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PM, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880
33. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway III KL (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91: 8132-8136
34. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
35. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580
36. Hornberg JJ, Bruggman FJ, Westerhoff HV, Lankelma J (2006) Cancer: a systems biology disease. BioSystems 83: 81-90
37. Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69: 373-398
38. Hunter T (2000) Signaling - 2000 and beyond. Cell 100: 113-127
39. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354
40. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120: 623-634
41. Jones RB, Gordus A, Krall JA, Macbeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439: 168-174
42. Kholodenko BN (2006) Cell signalling dynamics in time and space. Nat Rev Mol Cell Biol 7: 165-176
43. Kirschner M, Gerhart J (1998) Evolvability. Proc Natl Acad Sci USA 95: 8420-8427
44. Kitano H (2004a) Biological robustness. Nat Rev Genet 5: 826-837
45. Kitano H (2004b) Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 4: 227-234
46. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96: 4995-5000
47. Kolch W, Calder M, Gilbert D (2005) When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett 579: 1891-1895
48. Lanave C, Colangelo AM, Saccone C, Alberghina L (2007) Molecular evolution of the neurotrophin family members and their Trk receptors. Gene 394: 1-12
49. Lau LF, Nathans D (1987) Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. Proc Natl Acad Sci USA 84: 1182-1186
50. Leveugle M, Prat K, Popovici C, Birnbaum D, Coulier F (2004) Phylogenetic analysis of Ciona intestinalis gene superfamilies supports the hypothesis of successive gene expansions. J Mol Evol 158: 168-181
51. Lynch M, Conery JS (2000) The evolutionary fate and consequences of duplicate genes. Science 290: 1151-1155
52. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
53. Marmor MD, Yarden Y (2004) Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23: 2057-2070
54. Miyata T, Suga H (2001) Divergence pattern of animal gene families and relationship with the Cambrian explosion. Bioessays 23: 1018-1027
55. Morrison DK, Murakami MS, Cleghon V (2000) Protein kinases and phosphatases in the Drosophila genome. J Cell Biol 150: F57-F62
56. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127
57. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482
58. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215-223
59. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of eoidermal growth factor receptor signaling. Mol Syst Biol 1: 2005.0010
60. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787
61. Pao W, Miller VA, Politi KA, Rieli GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73
62. Pastor-Satorras R, Smith E, Sole RV (2003) Evolving protein interaction networks through gene duplication. J Theor Biol 222: 199-210
63. Pires-daSilva A, Sommer RJ (2003) The evolution of signalling pathways in animal development. Nat Rev Genet 4: 39-49
64. Rapp UR, Gotz R, Albert S (2006) BuCy RAFs drive cells into MEK addiction. Cancer Cell 9: 9-12
65. Rzhetsky A, Gomez SM (2001) Birth of scale-free molecular networks and the number of distinct DNA and protein domains per genome. Bioinformatics 17: 988-996
66. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554
67. Sangster TA, Lindquist S, Queitsch C (2004) Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 26: 348-362
68. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267: 381-383
69. Santos SD, Verveer PJ, Bastiaens PI (2007) Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 9: 324-330
70. Sassone-Corsi P, Lamph WW, Verma IM (1988) Regulation of protooncogene fos: a paradigm for early response genes. Cold Spring Harb Symp Quant Biol 53 (Pt 2): 749-760
71. Satou Y, Sasakura Y, Yamada L, Imai KS, Satoh N, Degnan B (2003) A genomewide survey of developmentally relevant genes in Ciona intestinalis. V. Genes for receptor tyrosine kinase pathway and Notch signaling pathway. Dev Genes Evol 213: 254-263
72. Schafer B, Gschwind A, Ullrich A (2004) Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23: 991-999
73. Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008
74. Shiu SH, Li WH (2004) Origins, lineage-specific expansions, and multiple losses of tyrosine kinases in eukaryotes. Mol Biol Evol 21: 828-840
75. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
76. Smolen P, Baxter DA, Byrne JH (2000) Mathematical modeling of gene networks. Neuron 26: 567-580
77. Stein RA, Staros JV (2000) Evolutionary analysis of the ErbB receptor and ligand families. J Mol Evol 50: 397-412
78. Stelling J, Sauer U, Szallasi Z, Doyle III FJ, Doyle J (2004) Robustness of cellular functions. Cell 118: 675-685
79. Tan PB, Kim SK (1999) Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. Trends Genet 15: 145-149
80. Tautz D (2000) Evolution of transcriptional regulation. Curr Opin Genet Dev 10: 575-579
81. Tsang M, Dawid IB (2004) Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Sci STKE 228: pe17
82. Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y (1998) Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J 17: 5948-5963
83. Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S (2005) TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 24: 3002-3010
84. van Staveren WC, Solis DW, Delys L, Venet D, Cappello M, Andry G, Dumont JE, Libert F, Detours V, Maenhaut C (2006) Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci USA 103: 413-418
85. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799
86. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10: 25-38
87. Weinstein IB (2002) Addiction to oncogenes: the Achilles' heal of cancer. Science 297: 63-64
88. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM (2004) Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694-699
89. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103: 7795-7800
90. Xiong W, Ferrell Jr JE (2003) A positive-feedback-based bistable 'memory module' that governs a cell fate decision. Nature 426: 460-465
91. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
92. Yates PR, Atherton GT, Deed RW, Norton JD, Sharrocks AD (1999) Id helix-loop-helix proteins inhibit nucleoprotein complex formation by the TCF ETS-domain transcription factors. EMBO J 18: 968-976
93. Yeger-Lotem Y, Sattath S, Kashtan N, Itzkovitz S, Milo R, Piner RY, Alon U, Magalit H (2004) Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction. Proc Natl Acad Sci USA 101: 5934-5999
94. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149
95. Zhang Y, Wolf-Yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger DA, White FM (2005) Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4: 1240-1250